



ABRIDGEMENT CERTIFICATE

To: Alberta Securities Commission
British Columbia Securities Commission
Ontario Securities Commission

Re: Annual and Special Meeting (the “Meeting”) of The Canadian Bioceutical Corporation (the “Corporation”) to be held on October 30, 2017

In connection with the abridgement of the time periods (the “Abridgement”) by the Corporation for notifying various regulatory authorities, exchanges and depositories of the record date and meeting date for the Meeting to be held on October 30, 2017, and for delivering requests for beneficial ownership information to certain participants and intermediaries in connection with the Meeting, the undersigned, W. Scott Boyes, President and Chief Executive Officer of the Corporation, hereby certifies for and on behalf of the Corporation and not in his personal capacity, that the Corporation has:

- (a) arranged to have proxy-related materials for the Meeting sent in compliance with the applicable timing requirements in Sections 2.9 and 2.12 of National Instrument 54-101 – *Communication with Beneficial Owners of Securities of a Reporting Issuer* (“NI 54-101”);
- (b) otherwise arranged to have carried out all of the requirements of NI 54-101 in addition to those described in paragraph (a) above; and
- (c) made the arrangements described in paragraphs (a) and (b) above and is relying upon Section 2.20 of NI 54-101 in making the Abridgement.

Dated: October 10, 2017

THE CANADIAN BIOCEUTICAL CORPORATION

Per: Signed: “W. Scott Boyes”
Name: W. Scott Boyes
Title: President and Chief Executive Officer